SI
SNDX icon

Sofinnova Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Sofinnova Investments’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,524,440
Closed -$14.3M – 73
2025
Q2 		$14.3M Sell
1,524,440
-750,783
-33% -$8.26M 0.87% 33
2025
Q1 		$28M Buy
2,275,223
+1,616,596
+245% +$22.8M 1.83% 16
2024
Q4 		$8.71M Sell
658,627
-128,372
-16% -$2.2M 0.63% 35
2024
Q3 		$15.1M Sell
786,999
-1,366,670
-63% -$28.2M 1.2% 21
2024
Q2 		$44.2M Buy
2,153,669
+545,129
+34% +$11.4M 2.3% 13
2024
Q1 		$38.3M Buy
1,608,540
+532,754
+50% +$11.9M 2.13% 16
2023
Q4 		$23.2M Buy
1,075,786
+133,969
+14% +$2.06M 1.3% 21
2023
Q3 		$13.7M Sell
941,817
-640,474
-40% -$12.1M 0.86% 32
2023
Q2 		$33.1M Buy
1,582,291
+506,867
+47% +$10.6M 2.17% 14
2023
Q1 		$22.7M Buy
1,075,424
+372,350
+53% +$9.26M 1.45% 20
2022
Q4 		$17.9M Buy
703,074
+178,072
+34% +$4.15M 1.06% 23
2022
Q3 		$12.6M Buy
525,002
+111,574
+27% +$2.5M 0.73% 28
2022
Q2 		$7.95M Sell
413,428
-303,636
-42% -$5.06M 0.66% 31
2022
Q1 		$12.5M Sell
717,064
-234,162
-25% -$3.94M 0.95% 27
2021
Q4 		$20.8M Buy
951,226
+537,385
+130% +$9.93M 1.22% 24
2021
Q3 		$7.91M Buy
+413,841
New +$6.9M 0.47% 45
2021
Q2 		– Sell
-298,644
Closed -$6.68M – 75
2021
Q1 		$6.68M Sell
298,644
-74,265
-20% -$1.68M 0.4% 44
2020
Q4 		$8.29M Buy
+372,909
New +$7.73M 0.49% 40
2020
Q3 		– Sell
-91,964
Closed -$1.36M – 86
2020
Q2 		$1.36M Buy
+91,964
New +$1.4M 0.09% 67
2019
Q4 		– Sell
-243,150
Closed -$1.82M – 69
2019
Q3 		$1.82M Buy
243,150
+421
+0.2% +$3.83K 0.16% 60
2019
Q2 		$2.26M Buy
242,729
+29,370
+14% +$214K 0.21% 53
2019
Q1 		$1.12M Sell
213,359
-136,751
-39% -$780K 0.11% 60
2018
Q4 		$1.56M Buy
350,110
+176,998
+102% +$970K 0.19% 55
2018
Q3 		$1.4M Buy
173,112
+74,499
+76% +$531K 0.12% 55
2018
Q2 		$693K Buy
98,613
+86,489
+713% +$849K 0.08% 55
2018
Q1 		$173K Buy
+12,124
New +$129K 0.03% 50

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Sofinnova Investments's SNDX Position: Q3 2025 in Review

Sofinnova Investments sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 1,524,440 shares — an estimated $14.3M sold.

Sofinnova Investments first reported a position in SNDX in Q1 2018 and held it in 26 quarters. The position peaked at $44.2M in Q2 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Sofinnova Investments reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sofinnova Investments sold 1,524,440 Syndax Pharmaceuticals shares in Q3 2025, an estimated $14.3M.
  • Sofinnova Investments first reported a position in Syndax Pharmaceuticals in Q1 2018 and held it in 26 quarters.
  • Sofinnova Investments's Syndax Pharmaceuticals position peaked at $44.2M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.